http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105237526-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99722ad50640e8d48b1c4a70ddf798d2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f5fb78a11673331d79836cb8921fc83 |
| publicationDate | 2016-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105237526-A |
| titleOfInvention | A kind of anti-HIV medicine and preparation method thereof |
| abstract | An anti-HIV drug and a preparation method thereof. The invention discloses a raltegravir derivative ester and a preparation method thereof. The chemical name of the raltegravir derivative ester is: N-(2'-(4 '-(4'-fluorobenzylcarbamoyl)-1'-methyl-6'-oxo-1',6'-dihydropyrimidin-2'-yl)-5'-methyl-1',3',4'-oxadiazole-2'-carboxamide-5'-oxo-{5-[1,4,8,11-tetraazacyclotetradecyl]methyl}phenyl)- 1,4,8,11-Tetraazacyclotetradecyl]}-R-carboxylate. It shows significantly higher activity (EC 50 ) and selectivity index (SI=EC 50 /CC 50 ) than reltegravir, and significantly increases solubility. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106632295-A |
| priorityDate | 2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.